TY  - JOUR
AU  - Mohlin, Sofie
AU  - Hansson, Karin
AU  - Radke, Katarzyna
AU  - Martinez, Sonia
AU  - Blanco-Aparicio, Carmen
AU  - Garcia-Ruiz, Cristian
AU  - Welinder, Charlotte
AU  - Esfandyari, Javanshir
AU  - O'Neill, Michael
AU  - Pastor Fernandez, Joaquin
AU  - von Stedingk, Kristoffer
AU  - Bexell, Daniel
PY  - 2019
DO  - 10.15252/emmm.201810058
SN  - 1757-4676
UR  - http://hdl.handle.net/20.500.12105/8209
AB  - The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL-302 is a novel highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL-302 in over 700 cell lines representing 47...
LA  - eng
PB  - Wiley
KW  - IBL-302
KW  - PI3K
KW  - cisplatin
KW  - multikinase inhibition
KW  - neuroblastoma
TI  - Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma
TY  - journal article
ER  -